Jana Phillips, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1477714731
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 445 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Amgen$825
- Novo Nordisk$625
- AstraZeneca$624
- Corcept Therapeutics$612
- Abbott$507
- plus $4K from 37 others
What the payments were for
- Food & beverage$8,229100%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,270 in reported general payments places this provider in the 60th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $524,419 |
| SomavertPegvisomant | 12 | $283,482 |
| OzempicSemaglutide | 193 | $245,969 |
| CrysvitaBurosumab-Twza | 12 | $208,993 |
| MounjaroTirzepatide | 117 | $142,300 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 98 | $114,296 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $101,644 |
| JardianceEmpagliflozin | 101 | $94,192 |
| FarxigaDapagliflozin Propanediol | 95 | $77,906 |
| MycapssaOctreotide Acetate | 12 | $76,446 |
| Tresiba Flextouch U-100Insulin Degludec | 97 | $64,182 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $60,683 |
| TrulicityDulaglutide | 44 | $53,552 |
| Repatha SureclickEvolocumab | 49 | $44,053 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 50 | $42,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $612 | $524,41913 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog, Fiasp | $625 | $400,304380 claims |
| PfizerSomavert | $97 | $283,48212 claims |
| Kyowa Kirin, Inc.Crysvita | $20 | $208,99312 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,155 | $202,000195 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $437 | $111,571124 claims |
| AstraZenecaFarxiga | $624 | $77,90695 claims |
| Chiesi USA, Inc.Mycapssa | $21 | $76,44612 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $251 | $42,14850 claims |
| AmgenProlia | $825 | $35,87022 claims |
| AbbVieSynthroid | $304 | $14,459199 claims |
| MerckJanuvia | $120 | $11,56813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Amanda SchieferJackson$204K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Robert EvansJackson$8K
- Christina GloverJackson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.